Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Sedatives and Hypnotics Drugs: Benzodiazepines

Sedatives and Hypnotics Drugs: Benzodiazepines

Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...

CNS Depressants: Barbiturates and Benzodiazepines

CNS Depressants: Barbiturates and Benzodiazepines

CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...

Anxiolytic Drugs: Benzodiazepines and Buspirone

Anxiolytic Drugs: Benzodiazepines and Buspirone

Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...

Sedatives and Hypnotics: Overview

Sedatives and Hypnotics: Overview

Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...

Sedatives and Hypnotics Drugs: Barbiturates

Sedatives and Hypnotics Drugs: Barbiturates

Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A key...

Anxiolytic Drugs: Overview

Anxiolytic Drugs: Overview

Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic circuitry.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A review of the management of antidepressant discontinuation symptoms.

Therapeutic advances in psychopharmacology·2016

Same author

Withdrawing Benzodiazepines in Patients With Anxiety Disorders.

Current psychiatry reports·2016

Same author

Usage of benzodiazepines: A review.

International journal of psychiatry in clinical practice·2014

Same author

Dependence and withdrawal: comparison of the benzodiazepines and selective serotonin re-uptake inhibitors.

Addiction (Abingdon, England)·2012

Same author

Satisfaction with medication is correlated with outcome but not persistence in patients treated with placebo, escitalopram, or serotonin-norepinephrine reuptake inhibitors: a post hoc analysis.

The primary care companion for CNS disorders·2011

Same author

Foreword. A comprehensive review of bupropion.

Clinical drug investigation·2011

Search research articles

Related Experiment Video

Updated: May 19, 2026

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster

Published on: October 20, 2023

Benzodiazepine harm: how can it be reduced?

Malcolm Lader¹

¹Institute of Psychiatry, London, UK.

British Journal of Clinical Pharmacology

|August 14, 2012

Summary

Benzodiazepines (BZDs) have significant risks, including dependence and withdrawal symptoms, especially with long-term use. Harm reduction strategies and alternative treatments are crucial for managing BZD use and abuse.

Area of Science:

Pharmacology
Clinical Medicine
Addiction Science

Background:

Benzodiazepines (BZDs) are widely prescribed for anxiety, insomnia, and seizures.
Long-term BZD use is common but poorly understood regarding efficacy and adverse effects.
Concerns exist regarding BZD dependence, withdrawal, abuse, and potential association with increased mortality.

Purpose of the Study:

To review the adverse effects, dependence, and withdrawal issues associated with benzodiazepines.
To discuss the implications of long-term benzodiazepine use and abuse.
To highlight harm reduction strategies and the importance of alternative treatments.

Main Methods:

Literature review and synthesis of existing data on benzodiazepine use, efficacy, and adverse effects.

Keywords:

adverse effects benzodiazepines reduction of harm

More Related Videos

Drug-Induced Sleep Endoscopy (DISE) with Target Controlled Infusion (TCI) and Bispectral Analysis in Obstructive Sleep Apnea

Drug-Induced Sleep Endoscopy (DISE) with Target Controlled Infusion (TCI) and Bispectral Analysis in Obstructive Sleep Apnea

Published on: December 6, 2016

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

Related Experiment Videos

Last Updated: May 19, 2026

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster

Published on: October 20, 2023

Drug-Induced Sleep Endoscopy (DISE) with Target Controlled Infusion (TCI) and Bispectral Analysis in Obstructive Sleep Apnea

Drug-Induced Sleep Endoscopy (DISE) with Target Controlled Infusion (TCI) and Bispectral Analysis in Obstructive Sleep Apnea

Published on: December 6, 2016

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

Analysis of withdrawal patterns, dependence, and abuse potential.

Examination of risk-benefit profiles and harm minimization principles.

Main Results:

Benzodiazepines can cause sedation, cognitive and psychomotor impairment, and paradoxical excitement.
Approximately one-third of long-term users experience withdrawal symptoms like anxiety, insomnia, and perceptual hypersensitivity.
Benzodiazepine abuse, often with other substances, and potential links to increased mortality are significant concerns.

Conclusions:

Benzodiazepines should not be first-line treatments and are best used short-term.
Effective harm reduction strategies include slow tapering for withdrawal and exploring alternative psychological and pharmacological treatments.
Managing benzodiazepine risks requires careful consideration of indications, patient selection, and addiction principles.